Solianis Monitoring AG

Solianis Monitoring AG on its Way to Success - Market Entry as Planned in 2011

Zurich (ots) - Solianis Monitoring AG presents its Non-Invasive, Continuous Glucose Monitoring System at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes (Basel, Switzerland, February 10-13, 2010). Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis, will present the concept of Solianis' proprietary Multisensor Glucose Monitoring System (MGMS) which in first tests under daily use conditions performed according expectations. "We are pleased with this progress" says Mario Stark, CEO of Solianis. "Currently we are setting up manufacturing and will subject our final prototype to rigorous clinical tests. These tests are the prerequisite to obtain CE approval for market entry in Europe in 2011. They will also give us the assurance that our MGMS is safe and provides people with diabetes with the information they and their healthcare professionals need. As an organization, we are expanding from a start-up enterprise towards a company which takes the responsibility to bring a reliable MGMS to market. Our ongoing interaction with scientific and clinical experts as well as patient groups ensures that MGMS becomes a system that meets the day-to-day needs of people with diabetes, their relatives and healthcare professionals". Solianis Monitoring AG is a Swiss medical device company developing an innovative non-invasive Continuous Glucose Monitoring (CGM) system for people with diabetes, their relatives and health care professionals. Its unique and proprietary technology is integrated in a Multisensor Glucose Monitoring System (MGMS) which continuously delivers information on glucose variations comparable to the minimally invasive devices currently approved by the FDA. Solianis was incorporated in May 2005 and has so far been funded by private investors, the Pioneer Fond of the Zurich Cantonal Bank and the EGS Beteiligungen AG. Solianis plans to introduce its first product for insulin dependent patients with diabetes in Europe in 2011, after product registration. ots Originaltext: Solianis Monitoring AG Internet: www.presseportal.ch Contact: Micaela Wochner Tel.: +41/44/306'80'29 Mobile: +41/79/431'79'34 E-Mail:micaela.wochner@solianis.com Internet: www.solianis.com Investors: Mario Stark Tel.: +41/44/306'80'40 Mobile: +41/79/542'88'74 E-Mail: Mario.stark@solianis.com

Das könnte Sie auch interessieren: